Previous 10 | Next 10 |
2023-10-30 17:33:34 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Biomea Fusion announces appointment of Juan Pablo Frías as chief medical officer Seeking Alpha’s Quant Rating on Biomea Fusion Historical e...
Demonstrated durable HbA1c lowering in the escalation portion of ongoing Phase II study in type 2 diabetes (COVALENT-111), with 84% of all patients showing a reduction of HbA1c after 4 weeks dosing and 74% after another 8 weeks off-treatment period Expansion portion of COVALENT-111 cleared an...
2023-10-19 17:11:44 ET Gainers: PacWest Bancorp ( PACW ) +7% . Biomea Fusion ( BMEA ) +5% . Bank OZK ( OZK ) +3% . ADMA Biologics ( ADMA ) +3% . Revance Therapeutics ( RVNC ) +3% . Losers: SolarEdge Technologies ( SEDG ...
BMF-500, a novel 3 rd generation oral covalent inhibitor of FMS-like tyrosine kinase 3 (FLT3), is the second product candidate discovered and developed by Biomea’s proprietary FUSION™ System to enter the clinic Phase I study (COVALENT-103) of BMF-500 will exami...
The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial of BMF-219 in adults with type 1 diabetes (T1D). The randomized, double-blind, placebo-controlled (N=150) trial in adults with T1D will examine the safety and efficacy of BMF-219 at two oral dose levels, 100 mg and ...
2023-10-05 05:30:00 ET More on Markets As 10-year Treasury yield pushes higher, Wolfe Research calls for 5% by year end Correction could be coming for mega caps - Wells Fargo Berenberg: Get defensive with healthcare, utilities and telecoms BlackRock is overwe...
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered at 100 mg and 200 mg, with dosing durations up to 12 weeks in type 2 diabetes patients The expansion portion will consist of approximately 300 patients and ...
2023-09-20 03:38:49 ET Summary Biomea Fusion's lead candidate BMF-219 shows mixed promise in treating diabetes and hematologic malignancies, but faces uncertainties like unclear mechanism of action. Financially, Biomea Fusion has robust liquidity with $222.9M in cash and no debt, ...
2023-08-31 08:43:59 ET More on Biomea Fusion Biomea Fusion: Potential Cure For Diabetes, Initiating With A Buy Jefferies downgrades Biomea to hold amid new data on diabetes drug Biomea Fusion jumps 19% after Phase 2 data for diabetes therapy Barclays bullish ...
Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes Steve Morris, M.D., will transition to the role of Chief Development Officer, continuing ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...